Main Article Content
OBJECTIVE: To study the outcome of children with retinoblastoma treated with primary chemotherapy.
METHODS: This was a hospital-based cohort prospective study of 91 children with retinoblastoma out of which 27 children (32 eyes) fulfilled the inclusion criteria. These children were admitted to Ophthalmology Unit, Lady Reading Hospital, Peshawar, Pakistan during the period of 1st January 2011 to 31st December 2013. Diagnosis was established by compatible history and ultrasonographic demonstration of posterior chamber mass with calcification. CT-Scan aided in diagnosis and also excluded extra scleral/intracranial extension. Examination under anesthesia allowed classifying the tumor according to Reese-Ellsworth classification system. Children of consenting parents were started on primary chemotherapy. Secondary treatment consisted of cryotherapy and/or argon laser photocoagulation.
RESULTS: The mean age of the cohort was 2.35 years. A total of 72% had advance stage IV or V disease. Secondary treatment was given in 43% eyes, whereas, 57% needed to be enucleated. Chemoreduction salvaged 43% of eyes. The mean survival in the cohort was 67.88 weeks and the Kaplan Meier cumulative 2 year survival rate is 77%. Primary chemotherapy improved survival in the cohort (none died). The test statistic (log rank is 20.04 (df-1); p<0.001). But, was not attributed to preventing globe loss (x2=2.52 (df-1), p=0.112). Preventing globe loss was attributed to the stage of the disease at time of diagnosis (x2=11.476 (df-1), p<0.001).
CONCLUSION: Primary chemotherapy improves survival but not globe salvage in children with retinoblastoma. Invariably, the deciding variable for vision and globe salvage is the stage of disease at diagnosis.
Work published in KMUJ is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
1. Memon F, Rathi SL, Memon MH. Pattern of solid pediatric malignant neoplasm at LUMHS, Jamshoro, Pakistan. J Ayub Med Coll Abbottabad 2007;19(4):55-7.
2. Abrahamson DH. Retinoblastoma in the 20th Century: Past success and future challenges. The Weisenfeld lecture. Investigative Ophthalmol & Visual Sci 2005 Aug;46(8):2684-91. DOI: 10.1167/iovs.04-1462.
3. Bonanomi MTBC, de-Almeida MTA, Cristofani LM, Filho OV. Retinoblastoma: a three-year-study at a Brazilian medical school hospital. Clinics 2009;64(5):427-34. DOI: 10.1590/S1807-59322009000500010.
4. Broaddus E, Tophan A, Singh AD. Incidence of retinoblastoma in the United States: 1975–2004. Br J Ophthalmol 2009 Jan;93(1):21-3. DOI: 10.1136/bjo.2008.138750.
5. Murphree AL, Samuel MA, Harbour JW, Mansfield NC. Retinoblastoma in Ryan SJ. St. Louis: 3rd ed. Retina mosby-Year Book, Inc; 2006:568.
6. Usmanov RH, Kivelä T. Predicted Trends in the Incidence of Retinoblastoma in the Asia-Pacific Region. Asia Pac J Ophthalmol (Phila) 2014 May-Jun;3(3):151-7. DOI: 10.1097/APO.0000000000000060
7. Balmer A, Munier F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma. Clinical Ophthalmol 2007 Dec;1(4):431-9.
8. Arif M, Kundi NK. Ultrasonography in diagnosis of retinoblastoma. Pak J Med Res 2010;49(1):18-20.
9. Gombos DS, Kelly A, Coen PG, Kingston JE, Hungerford JL. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 2002;86:80-3. DOI: 10.1136/bjo.86.1.80.
10. Shields CL, Meadows AT, Leahy AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 2004;24(6):849-62. DOI: 10.1097/00006982-200412000-00001.
11. Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114(11):1321-8. DOI: 10.1001/archopht.1996.01100140521001.
12. Shields CL, Shields JA, Needle M, de Potter P, Kheteral S, Hamada A, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997;104(12):2101-11. DOI: 10.1016/S0161-6420(97)30053-0.
13. Murphree AL, Villablanca JG, Deegan WF 3rd, Sato JK, Malogolowkin M, Fisher A, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114(11):1348-56. DOI: 10.1001/archopht.1996.01100140548005.
14. Zafar SN, Siddiqui SN, Zaheer N. Tumor regression patterns in retinoblastoma. J Coll Physicians Surg Pak 2016;26(11):896-9.
15. Kingston JE, Hungerford JL, Madreperla SA, Plouman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114(11):1339-43. DOI: 10.1001/archopht.1996.01100140539004.
16. Iqbal Z, Saeed TM. Frequency of retinoblastoma at Lady Reading Hospital, Peshawar, Pakistan. Asian J Ophthalmol 2011;12(3):140-3.
17. Waddell KM, Kagame K, Ndamira A, Twinamasiko A, Picton SV, Simmons IG, et al. Improving survival of retinoblastoma in Uganda. Br J Ophthalmol 2015;99(7):937-42. DOI: 10.1136/bjophthalmol-2014-306206.
18. Kim JH, Yu YS, Khwarg SI, Choi HS, Shin HY, Ahn HS. Clinical result of prolonged primary chemotherapy in retinoblastoma patients. Korean J Ophthalmol 2003;17(1):35-43. DOI: 10.3341/kjo.2003.17.1.35.
19. Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21(10):2019-25. DOI: 10.1200/JCO.2003.09.103.
20. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: Evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007;114(1):162-9. DOI: 10.1016/j.ophtha.2006.06.042.
21. Shields CL, Mashayekhi A, Au AK, Czyz C, Leathey A, Meadows At, et al. The International classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113(11):2276-80. DOI: 10.1016/j.ophtha.2006.06.018.
22. Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998;116(7):887-93. DOI:10.1001/archopht.116.7.887.
23. Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B, Chan HS, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol 2001;29(7):845-51. DOI: 10.1200/JCO.2010.32.5332.
24. Shields CL, Honavar SG, Meadows ST, Shields JA, Demirci H, Singh A, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external bean radiotherapy or enucleation. Am J Ophthalmol 2002;133(5):657-64. DOI: 10.1016/S0002-9394(02)01348-X.